MA40968A - Polythérapie à base d'anticorps anti-egfr - Google Patents
Polythérapie à base d'anticorps anti-egfrInfo
- Publication number
- MA40968A MA40968A MA040968A MA40968A MA40968A MA 40968 A MA40968 A MA 40968A MA 040968 A MA040968 A MA 040968A MA 40968 A MA40968 A MA 40968A MA 40968 A MA40968 A MA 40968A
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- polytherapy
- egfr antibody
- adc
- antibody
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 101710112752 Cytotoxin Proteins 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 239000000611 antibody drug conjugate Substances 0.000 abstract 1
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 239000002619 cytotoxin Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Les anticorps anti-egfr peuvent être combinés pour améliorer leur effet anticancéreux. Dans la présente invention, au moins l'un de deux anticorps nus dans une combinaison est fourni en tant que conjugué de médicament d'anticorps (adc) dans lequel l'anticorps est couplé à une cytotoxine. Les deux anticorps peuvent également être fournis sous forme d'adc. Le résultat est une activité améliorée, l'amélioration étant synergique dans de nombreuses paires d'anticorps de ce type.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462073380P | 2014-10-31 | 2014-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40968A true MA40968A (fr) | 2017-10-04 |
Family
ID=55856303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040968A MA40968A (fr) | 2014-10-31 | 2015-10-30 | Polythérapie à base d'anticorps anti-egfr |
Country Status (5)
Country | Link |
---|---|
US (1) | US20170333570A1 (fr) |
EP (1) | EP3223857A4 (fr) |
CA (1) | CA2965362A1 (fr) |
MA (1) | MA40968A (fr) |
WO (1) | WO2016065456A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI750194B (zh) * | 2016-07-05 | 2021-12-21 | 大陸商江蘇恆瑞醫藥股份有限公司 | Egfr抗體-藥物偶聯物及其在醫藥上的應用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1549344T1 (sl) * | 2002-10-10 | 2015-05-29 | Merck Patent Gmbh | FARMACEVTSKI SESTAVKI PROTI RECEPTORJEM ErbB1 |
WO2008104183A2 (fr) * | 2007-03-01 | 2008-09-04 | Symphogen A/S | Compositions d'anticorps recombinants dirigés contre le récepteur du facteur de croissance épidermique |
MX2012012441A (es) * | 2010-05-04 | 2013-02-26 | Merrimack Pharmaceuticals Inc | Anticuerpos contra el receptor del factor de crecimiento epidermico (egfr) y usos de los mismos. |
AU2011320314B2 (en) * | 2010-10-29 | 2015-08-06 | Immunogen, Inc. | Novel EGFR-binding molecules and immunoconjugates thereof |
PT2668209T (pt) * | 2011-01-24 | 2021-04-07 | Gilead Sciences Inc | Anticorpos seletivos para células que apresentam egfr em alta densidade |
EA201991268A3 (ru) * | 2011-03-29 | 2020-01-31 | Иммуноджен, Инк. | Получение конъюгатов "майтансиноид-антитело" одностадийным способом |
SG11201402343SA (en) * | 2011-11-21 | 2014-06-27 | Immunogen Inc | Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate |
KR102305226B1 (ko) * | 2013-03-15 | 2021-09-29 | 아비에 도이치란트 게엠베하 운트 콤파니 카게 | 항-egfr 항체 약물 접합체 제형 |
-
2015
- 2015-10-30 MA MA040968A patent/MA40968A/fr unknown
- 2015-10-30 WO PCT/CA2015/000557 patent/WO2016065456A1/fr active Application Filing
- 2015-10-30 CA CA2965362A patent/CA2965362A1/fr not_active Abandoned
- 2015-10-30 US US15/522,975 patent/US20170333570A1/en not_active Abandoned
- 2015-10-30 EP EP15854690.3A patent/EP3223857A4/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CA2965362A1 (fr) | 2016-05-06 |
EP3223857A4 (fr) | 2018-06-27 |
WO2016065456A1 (fr) | 2016-05-06 |
US20170333570A1 (en) | 2017-11-23 |
EP3223857A1 (fr) | 2017-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019002250A1 (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. (divisional solicitud 201803520) | |
AR117913A2 (es) | Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
MA39034A1 (fr) | Composés de quinoline sélectivement substitués | |
EA201270815A1 (ru) | Модуляторы рецепторов эстрогена и их применение | |
EA201591403A1 (ru) | Спиролактамные модуляторы рецептора nmda и их применение | |
EA201591404A1 (ru) | Спиролактамные модуляторы рецептора nmda и их применение | |
EA201692177A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
EA201591402A1 (ru) | Спиролактамные модуляторы nmda-рецептора и их применение | |
ECSP16068524A (es) | Insulina de acción prolongada y uso de la misma | |
PE20141019A1 (es) | Nuevos inmunoconjugados | |
EA201491530A1 (ru) | Модуляторы рецепторов эстрогенов и их применение | |
MA37946A1 (fr) | Traitement de la polyarthrite rhumatoïde | |
MA39254A1 (fr) | Anticorps stables à affinité élevée et agrégatifs à base de domaines viraux vl et de dérivé de vhh | |
MA40875A (fr) | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux | |
MA39335B1 (fr) | Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone | |
WO2018067520A3 (fr) | Procédés et agents thérapeutiques | |
EA202191175A1 (ru) | Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры | |
MX2022001146A (es) | Formulaciones de anticuerpos anti-pvrig y sus usos. | |
CL2018000131A1 (es) | Inmunoconjugados de il22 | |
ZA202107825B (en) | Pharmaceutical parenteral composition of dual glp1/2 agonist | |
FR3063645B1 (fr) | Acefapc pour le traitement des maladies acetylcholine dependantes | |
EP4293116A3 (fr) | Fibrinogène liquide stable | |
MA52076A (fr) | Anticorps anti-cd137 pour une combinaison avec des anticorps anti-pd-1 | |
EA201992883A1 (ru) | АНТИТЕЛА К TrkB | |
MA40968A (fr) | Polythérapie à base d'anticorps anti-egfr |